D iabetes mellitus (DM) and hypertension are major public health problems that are frequently encountered in clinical practice. Recent trends show a steady increase in the prevalence of both DM and hypertension, especially in nonwhite ethnic groups, and it is likely that these trends will continue to show increases owing to the increasing number of elderly and obese individuals in the United States. It is estimated that by 2050, nearly 50 million Americans will have DM, and Ϸ100 million will have hypertension. These 2 conditions often coexist. The prevalence of hypertension in DM is Ϸ2 times that observed in the general population, and as many as 70% to 80% of diabetic patients have hypertension.
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The role of DM as a risk factor for cardiovascular (CV) events is well established. It is known that as many as 70% of diabetic patients die secondary to CV disease. A recent meta-analysis of 102 prospective studies involving 698 782 individuals with 8.49 million years of follow-up showed that DM confers a 2-fold excess risk for coronary heart disease, major strokes, and deaths attributable to other vascular diseases. 1 From the calculations in this meta-analysis, it is estimated that 10% of all adult vascular deaths in developed countries can be attributed to DM. Hypertension is well established as a risk factor for all major CV events. The presence of hypertension in patients with DM significantly increases the risk of myocardial infarction, stroke, and allcause mortality. The coexistence of the 2 conditions also increases the risk of heart failure, nephropathy, and other microvascular events. 2 Because of the significant increase in the risk of major macrovascular and microvascular events in diabetic patients with hypertension, considerable efforts have been made during the past several decades to pursue various interventional strategies directed toward control of blood pressure (BP) with the hope that such treatment can significantly lower the increased risk of CV events. Although early data from the landmark trials such as the United Kingdom Prospective Diabetes Study (UKPDS) 3 and Hypertension Optimal Treatment (HOT) study 4 clearly indicated that aggressive BP control was highly beneficial in patients with DM, the recent findings of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) 5 and Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) 6 studies are somewhat perplexing in that they challenge the prevailing concept that the lower the BP, the better. The results of these studies have raised the question, is lower BP always better, and how low should it go to get maximum CV protection without inducing harm?
There is no clear optimal target BP in diabetic patients with hypertension. The results of the meta-analysis by Bangalore et al 7 published in the current issue of Circulation provide some answers by analyzing the data from 13 randomized clinical trials (RCTs) of 37 736 patients with DM or impaired fasting glucose/impaired glucose tolerance in which it was possible to compare the outcomes in those with intensive BP control (target systolic BP [SBP] Յ135 mm Hg) and standard BP control (target SBP Յ140 mm Hg). Although, as seen in most meta-analyses, there are problems of heterogeneity of patient population, the presence of comorbid conditions, and variations in the treatments used, the results provide some interesting and clinically relevant findings that shed further light on the optimal target BP levels in patients with DM and hypertension.
Is Lower Blood Pressure Really Always Better: The Evidence
The concept of lower is better as it relates to SBP in patients with DM and hypertension is based largely on an observation made from the epidemiological data from landmark studies such as Multiple Risk Factor Intervention Trial (MRFIT), UKPDS, and others. 2 Although these studies did indeed show that increasing levels of SBP (starting as low as 115 mm Hg) were associated with a higher risk of macrovascular events in patients with DM and hypertension, there is no evidence from these or other RCTs to support the prevailing notion that achieving lower SBP levels Ͻ130 mm Hg with antihypertensive drugs is indeed beneficial in reducing the increased risk of CV events. The classic RCTs, such as UKPDS and HOT, had shown the benefit of aggressive BP control, but it is important to remember that in both studies the achieved SBP in the aggressive control arm was 144 mm Hg. 3, 4 However, largely on the basis of the prevailing concept (even in the absence of any evidence from RCTs), various guideline committees had recommended that in patients with DM and hypertension, the target BP should be Ͻ130/80 mm Hg (and even lower to 125/75 mm Hg in those with renal impairment). The findings from the recent RCTs specifically examining the role of an intensive BP-lowering strategy to achieve SBP Յ135 mm Hg raise questions about the basis of such 5, 6, 8 These findings are further corroborated by the results of the meta-analysis by Bangalore et al. 7 They have shown that the totality of data from the available RCTs examining the role of intensive BP lowering in patients with DM, impaired fasting glucose, or impaired glucose tolerance do not support an across-the-board strategy of lowering SBP to Յ135 mm Hg because their findings did not reveal significant benefit of intensive BP-lowering strategy over the standard BP control strategy on macrovascular and microvascular (cardiac, renal, and retinal) events. However, similar to findings from several RCTs, their results showed that more intensive SBP control (SBP Ͻ130 mm Hg) was associated with a greater reduction in risk of stroke. 3, 5, 7 The discordant findings of an intensive BP-lowering strategy on the risks of myocardial infarction and stroke are interesting and not entirely unexpected. It is well known from previous data that excessive lowering of SBP in patients with preexisting coronary heart disease (especially in the presence of structural heart disease such as left ventricular hypertrophy or dysfunction) could be associated with an increased risk of myocardial infarction secondary to a progressive fall in the coronary perfusion pressures across the diseased segments of the coronary arteries caused by impairment of coronary autoregulation when BP falls. 8 -11 In contrast, the observed stroke reduction in the meta-analysis by Bangalore et al 7 and the ACCORD study 5 is consistent with data from observational studies that showed a linear relationship between increasing SBP levels and risk of stroke, as well as a decrease in stroke risk with lowering of SBP to levels Ͻ120 mm Hg. 12, 13 Furthermore, the data from the Perindopril Protection Against Recurrent Stroke Study (PROGRESS) 14 showed that in survivors of prior stroke, there was a progressive reduction in the recurrence of ischemic and hemorrhagic strokes in that the on-treatment SBP went down to Ͻ115 mm Hg. In this study, there was no evidence for a J-curve phenomenon in survivors of stroke, and the benefit of lowering SBP on recurrence of stroke was evident even in those who started with a baseline median SBP of 114 mm Hg. 14 These data could be explained by the direct and close relationship of stroke with SBP or by the fact that there is an excellent autoregulation of the cerebral blood flow that allows the continued perfusion of the brain even at low BP values. 15
How Low Should the Blood Pressure Go?
The precise answer to this question is difficult and cannot be given on the basis of the available evidence. However, it appears that there is heterogeneity of the effects of intensive BP lowering on coronary versus cerebral events, and the effects can also vary on the basis of the presence or absence of comorbid conditions in a given individual, as well as the subsequent risk of various events. The data available so far from RCTs suggest that in patients with preexisting CV disease, specifically coronary heart disease, it is prudent not to lower SBP to Յ135 mm Hg. In contrast, in those at higher risk of stroke (such as Asian patients) who do not have preexisting coronary heart disease, it may be beneficial to reduce SBP to Ͻ120 mm Hg if this can be accomplished safely. In addition, in patients with preexisting renal disease or those at high risk for other microvascular disease, data suggest that it might also be beneficial to reduce the SBP to Ͻ120 mm Hg. However, more data are needed to support such a broad-based recommendation.
Safety Concerns and Alternative Approaches
One major concern with the intensive BP-lowering strategy is the side effects of and adverse reactions to the multiple drugs needed to attain goal BP. Both the ACCORD study 5 
and the Ongoing Telmisartan Alone and in Combination With
Ramipril Global Endpoint Trial (ONTARGET) 10 demonstrated that the use of multiple antihypertensive drugs is associated with a significantly higher incidence of serious adverse effects, such as significant hypotension, syncope, and worsening renal function. It is likely that such serious adverse effects might counteract any beneficial effects of such a strategy and should be avoided. Recent data from the Action for Health in Diabetes (Look-AHEAD) study showed that lifestyle intervention can have a significant favorable effect on various metabolic parameters, as well as BP and lipid levels, without any adverse consequences. 16 Although the long-term impacts of these changes on CV outcomes are not yet established, there is certainly reason to consider these alternative approaches in addition to drug therapy to avoid excessive risk of serious adverse effects associated with the incremental number of drugs needed for intensive BP control.
Lessons Learned and Look to the Future
The findings from the meta-analysis by Bangalore et al, 7 along with the results of other recent RCTs, emphasize several important points. First, it is important to recognize that not all patients are created alike, that there is significant heterogeneity of patients and our treatment strategy needs to be adjusted accordingly. Second, although it is important to recognize the prognostic importance of a biomarker such as BP, it is also crucial to keep in mind that there is a difference in the impact on CV outcomes of natural levels of a biomarker such as BP compared with the levels achieved with the use of pharmacological interventions, which might not always translate into beneficial effects. It is therefore essential to document the evidence of benefit in RCTs before rushing to recommend aggressive strategies, especially when there is potential for harm. In the future, more RCTs are needed to carefully examine the discordant results of intensive BP lowering on various events in patients with DM and hypertension and to define optimal BP targets.
